Aptahem

Aptahem Debt

Debt of Aptahem (APTA.SL) as of Oct 28, 2026.

Debt

0.00SEK

Last updated:

In 2024, Aptahem's total debt was 0.00 SEK, a % change from the 5.00 M SEK total debt recorded in the previous year.

The Aptahem Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
0.00 SEK
Jan 1, 2018
0.00 SEK
Jan 1, 2019
0.00 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
5.00 M SEK
Jan 1, 2024
0.00 SEK
The Aptahem Debt history
YEARDebtYoY
0.00SEK-100.00%
5.00 MSEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptahem Stock analysis

What does Aptahem do? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem is one of the most popular companies on Eulerpool.

Debt Details

Understanding Aptahem's Debt Structure

Aptahem's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Aptahem's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Aptahem’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Aptahem’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Aptahem stock

On Eulerpool you can find the complete historical development of Debt Aptahem since 2006 – with annual values, charts, and detailed analysis.

Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Aptahem historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptahem

All Key Metrics — Aptahem